MULTICOMPONENT CRYSTALS COMPRISING DASATINIB AND SELECTED COCRYSTAL FORMERS

摘要

FIELD: biochemistry.;SUBSTANCE: invention relates to a multicomponent crystalline system (co-crystal) comprising a compound of formula 1 and a second compound selected from methyl 4-hydroxybenzoate or nicotinamide or ethyl gallate, or methyl gallate, or ethyl maltol, or vanillin, or (1R,2S,5R)-(-)-menthol. Molar ratio in the multicomponent crystalline system for the compound of formula 1 and the second compound is in the range of from 4:1 to 1:1. Multicomponent crystalline system of the invention is intended as an agent for the treatment of chronic myelogenous leukemia and/or acute lymphoblastic leukemia with the expression of the Philadelphia chromosome. .;EFFECT: multicomponent crystalline system has improved solubility.;13 cl, 7 dwg, 7 ex, 7 tbl